A major change to her prescription benefits meant the medication she was using to manage her weight – a treatment that had ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

Expenditures could rise nearly 8% this year, pressuring employers as healthcare costs eat up a larger share of their budgets, ...